- Due the low prevalence of some diseases, the study will be comprised of 3 single disease cohorts (ependymoma, malignant or atypical meningioma, chordoma) for which accrual is likely to be robust and a fourth cohort for the remaining 9 diseases which are very rare and this trial will look for a preliminary signal. Each cohort will be evaluated independently for efficacy.